1. kirkskraft
2. dwaysche
3. lieselloveszach
4. 4tokoma4tokoma
5. nlanas2sk051p
1.4tokoma4tokoma 02/22/2018
We should be over 40 by now
2.lieselloveszach 03/06/2018
Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
3.dwaysche 02/21/2018
Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
4.4tokoma4tokoma 01/09/2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
5.lieselloveszach 06/28/2018
Cantor Fitzgerald reiterates Buy rating, $42 PT
6.dwaysche 02/22/2018
ADDING MONEY IN THE BANK!
7.lieselloveszach 06/08/2018
Piper Jaffray sets PT at $48
8.kirkskraft 02/22/2018
Will be in the 40 range soon.
9.kirkskraft 04/03/2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
10.kirkskraft 03/01/2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW